Brain magnetic resonance spectroscopy;Spectroscopie par résonance magnétique céré brale

Journal de Radiologie

Volumn 88, Issue 3 C2, 2007, Pages 483-496

  Galanaud, D ^a   Nicoli, F ^b   Confort Gouny, S ^b   Le Fur, Y ^b   Dormont, D ^a   Girard, N ^b   Ranjeva, J P ^b   Cozzone, P J ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CNRS   (France)

Author keywords

Magnetic resonance spectroscopy; MRI

Indexed keywords

ADRENOLEUKODYSTROPHY; ARTICLE; AUTOMATION; BRAIN ABSCESS; BRAIN DISEASE; BRAIN INJURY; BRAIN METABOLISM; BRAIN RADIOGRAPHY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EXAMINATION; DIFFERENTIAL DIAGNOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMAGE QUALITY; MEDICAL RESEARCH; METABOLIC DISORDER; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; SCLEROSIS; TUMOR DIAGNOSIS; TUMOR NECROSIS;

EID: 34247172542     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0221-0363(07)89848-9     Document Type: Article

References (68)

1. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13:129-53.
2. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001;265:54-84.
3. Girard N, Fogliarini C, Viola A, Confort-Gouny S, Fur YL, Viout P, et al. MRS of normal and impaired fetal brain development. Eur J Radiol 2006;57:217-25.
4. Kok RD, van den Berg PP, van den Bergh AJ, Nijland R, Heerschap A. Maturation of the human fetal brain as observed by 1H MR spectroscopy. Magn Reson Med 2002;48:611-6.
5. Kreis R, Ernst T, Ross BD. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 1993;30:424-37.
6. Girard N, Gouny SC, Viola A, Le Fur Y, Viout P, Chaumoitre K, et al. Assessment of normal fetal brain maturation in utero by proton magnetic resonance spectroscopy. Magn Reson Med 2006;56:768-75.
7. Ross AJ, Sachdev PS, Wen W, Brodaty H. Longitudinal changes during aging using proton magnetic resonance spectroscopy. J Gerontol A Biol Sci Med Sci 2006;61:291-8.
8. Sijens PE, den Heijer T, Origgi D, Vermeer SE, Breteler MM, Hofman A, et al. Brain changes with aging: MR spectroscopy at supraventricular plane shows differences between women and men. Radiology 2003;226:889-96.
9. Katz-Brull R, Koudinov AR, Degani H. Choline in the aging brain. Brain Res 2002;951:158-65.
10. Brooks JC, Roberts N, Kemp GJ, Gosney MA, Lye M, Whitehouse GH. A proton magnetic resonance spectroscopy study of age-related changes in frontal lobe metabolite concentrations. Cereb Cortex 2001;11:598-605.
11. Leary SM, Brex PA, MacManus DG, Parker GJ, Barker GJ, Miller DH, et al. A (1)H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. Magn Reson Imaging 2000;18:455-9.
12. Sijens PE, Oudkerk M, de Leeuw FE, de Groot JC, Achten E, Heijboer R, et al. 1H chemical shift imaging of the human brain at age 60-90 years reveals metabolic differences between women and men. Magn Reson Med 1999;42:24-31.
13. Galanaud D, Le Fur Y, Nicoli F, Denis B, Confort-Gouny S, Ranjeva JP, et al. Regional metabolite levels of the normal posterior fossa studied by proton chemical shift imaging. Magma 2001;13:127-33.
14. Barba I, Moreno A, Martinez-Perez I, Tate AR, Cabanas ME, Baquero M, et al. Magnetic resonance spectroscopy of brain hemangiopericytomas: high myoinositol concentrations and discrimination from meningiomas. J Neurosurg 2001;94:55-60.
15. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000;21:1645-9.
16. Bendszus M, Warmuth-Metz M, Burger R, Klein R, Tonn JC, Solymosi L. Diagnosing dural metastases: the value of 1H magnetic resonance spectroscopy. Neuroradiology 2001;43:285-9.
17. Cho YD, Choi GH, Lee SP, Kim JK. (1)H-MRS metabolic patterns for distinguishing between meningiomas and other brain tumors. Magn Reson Imaging 2003;21:663-72.
18. Grand S, Passaro G, Ziegler A, Esteve F, Boujet C, Hoffmann D, et al. Necrotic tumor versus brain abscess: importance of amino acids detected at 1H MR spectroscopy-initial results. Radiology 1999;21:785-93.
19. Galanaud D, Chinot O, Metellus P, Cozzone P. Apports de la spectroscopie par résonance magnétique dans l'exploration des gliomes. Bull Cancer 2005;92:327-31.
20. Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371-81.
21. Chen CJ. Serial proton magnetic resonance spectroscopy in lesions of Balo concentric sclerosis. J Comput Assist Tomogr 2001;25:713-8.
22. Nicoli F, Lefur Y, Denis B, Ranjeva JP, Confort-Gouny S, Cozzone PJ. Metabolic counterpart of decreased apparent diffusion coefficient during hyperacute ischemic stroke: a brain proton magnetic resonance spectroscopic imaging study. Stroke 2003;34:e82-7.
23. Parsons MW, Li T, Barber PA, Yang Q, Darby DG, Desmond PM, et al. Combined (1)H MR spectroscopy and diffusion-weighted MRI improves the prediction of stroke outcome. Neurology 2000;55:498-505.
24. Herminghaus S, Dierks T, Pilatus U, Möller-Hartmann W, Wittsack J, Marquardt G, et al. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003;98:74-81.
25. Stadlbauer A, Gruber S, Nimsky C, Fahlbusch R, Hammen T, Buslei R, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006;238:958-69.
26. Galanaud D, Chinot O, Nicoli F, Confort-Gouny S, Le Fur Y, Barrié-Attarian M, et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from lowgrade glioma. J Neurosurg 2003;98:269-76.
27. Nelson SJ, Graves E, Pirzkall A, Li X, Antiniw Chan A, Vigneron DB, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002;16:464-76.
28. Murphy PS, Viviers L, Abson C, Rowland IJ, Brada M, Leach MO, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004;90:781-6.
29. Kimura T, Sako K, Tanaka K, Gotoh T, Yoshida H, Aburano T, et al. Evaluation of the response of metastatic brain tumors to stereotactic radiosurgery by proton magnetic resonance spectroscopy, 201TlCl single-photon emission computerized tomography, and gadolinium-enhanced magnetic resonance imaging. J Neurosurg 2004;100:835-41.
30. Lichy MP, Plathow C, Schulz-Ertner D, Kauczor HU, Schlemmer HP. Follow-up gliomas after radiotherapy: 1H MR spectroscopic imaging for increasing diagnostic accuracy. Neuroradiology 2005;47:826-34.
31. Yoshino E, Ohmori Y, Imahori Y, Higuchi T, Furuya S, Naruse S, et al. Irradiation effects on the metabolism of metastatic brain tumors: analysis by positron emission tomography and 1H-magnetic resonance spectroscopy. Stereotact Funct Neurosurg 1996;66 (Suppl 1):240-59.
32. De Edelenyi FS, Rubin C, Esteve F, Grand S, Decorps M, Lefournier V, et al. A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nat Med 2000;6:1287-9.
33. Galanaud D, Nicoli F, Chinot O, Confort-Gouny S, Figarella-Branger D, Roche P, et al. Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. Magn Reson Med 2006;55:1236-45.
34. Zarifi MK, Astrakas LG, Poussaint TY, Plessis Ad A, Zurakowski D, Tzika AA. Prediction of adverse outcome with cerebral lactate level and apparent diffusion coefficient in infants with perinatal asphyxia. Radiology 2002;225:859-70.
35. Kadri M, Shu S, Holshouser B, Deming D, Hopper A, Peverini R, et al. Proton magnetic resonance spectroscopy improves outcome prediction in perinatal CNS insults. J Perinatol 2003;23:181-5.
36. Cheong JL, Cady EB, Penrice J, Wyatt JS, Cox IJ, Robertson NJ. Proton MR spectroscopy in neonates with perinatal cerebral hypoxic-ischemic injury: metabolite peak-area ratios, relaxation times, and absolute concentrations. AJNR Am J Neuroradiol 2006;27:1546-54.
37. Boichot C, Walker PM, Durand C, Grimaldi M, Chapuis S, Gouyon JB, et al. Term neonate prognoses after perinatal asphyxia: contributions of MR imaging, MR spectroscopy, relaxation times, and apparent diffusion coefficients. Radiology 2006;239:839-48.
38. Lescot T, Carpentier A, Galanaud D, Puybasset L. IRM céré brale en neurotraumatologie. Ann Fr Anesth Reanim 2005;24:516-21.
39. Ross BD, Ernst T, Kreis R, Haseler LJ, Bayer S, Danielsen E, et al. 1H MRS in acute traumatic brain injury. J Magn Reson Imaging 1998;8:829-40.
40. Uzan M, Albayram S, Dashti SG, Aydin S, Hanci M, Kuday C. Thalamic proton magnetic resonance spectroscopy in vegetative state induced by traumatic brain injury. J Neurol Neurosurg Psychiatry 2003;74:33-8.
41. Carpentier A, Galanaud D, Puybasset L, Muller JC, Lescot T, Boch AL, et al. Early morphologic and spectroscopic magnetic resonance in severe traumatic brain injuries can detect "invisible brain stem damage" and predict "vegetative states". J Neurotrauma 2006;23:674-85.
42. Deslauriers R, Saunders JK, McIntyre MC. Magnetic resonance studies of the effects of cardiovascular surgery on brain metabolism and function. J Cardiothorac Vasc Anesth 1996;10:127-37; quiz 137-8.
43. Krep H, Bottiger BW, Bock C, Kerskens CM, Radermacher B, Fischer M, et al. Time course of circulatory and metabolic recovery of cat brain after cardiac arrest assessed by perfusion- and diffusion-weighted imaging and MR-spectroscopy. Resuscitation 2003;58:337-48.
44. Macmillan CS, Wild JM, Wardlaw JM, Andrews PJ, Marshall I, Easton VJ. Traumatic brain injury and subarachnoid hemorrhage: in vivo occult pathology demonstrated by magnetic resonance spectroscopy may not be "ischaemic" . A primary study and review of the literature. Acta Neurochir (Wien) 2002;144:853-62; discussion 862.
45. Salvan AM, Vion-Dury J, Confort-Gouny S, Nicoli F, Lamoureux S, Cozzone PJ. Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy. AIDS Res Hum Retroviruses 1997;13:1055-66.
46. Vion-Dury J, Nicoli F, Salvan AM, Confort-Gouny S, Dhiver C, Cozzone PJ. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet 1995;345:60-1.
47. Chang L, Ernst T, Tornatore C, Aronow H, Melchor R, Walot I, et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997;48:836-45.
48. Katz-Brull R, Lenkinski RE, Du Pasquier RA, Koralnik IJ. Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy. Neurology 2004;63:897-900.
49. Viola A, Nicoli F, Denis B, Confort-Gouny S, Le Fur Y, Ranjeva JP, et al. High cerebral scyllo-inositol: a new marker of brain metabolism disturbances induced by chronic alcoholism. Magma 2004;17:47-61.
50. Kreis R, Farrow N, Ross BD. Diagnosis of hepatic encephalopathy by proton magnetic resonance spectroscopy. Lancet 1990;336:635-6.
51. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117 (Suppl 1):49-58.
52. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121 (Suppl 8):1469-77.
53. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43:56-71.
54. Ranjeva JP, Pelletier J, Confort-Gouny S, Ibarrola D, Audoin B, Le Fur Y, et al. MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2003;9:554-65.
55. Kaufmann P, Shungu DC, Sano MC, Jhung S, Engelstad K, Mitsis E, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004;62:1297-302.
56. Lin DD, Crawford TO, Barker PB. Proton MR spectroscopy in the diagnostic evaluation of suspected mitochondrial disease. AJNR Am J Neuroradiol 2003;24:33-41.
57. Oz G, Tkac I, Charnas LR, Choi IY, Bjoraker KJ, Shapiro EG, et al. Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology 2005;64:434-41.
58. Confort-Gouny S, Vion-Dury J, Chabrol B, Nicoli F, Cozzone PJ. Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy. Neuroradiology 1995;37:568-75.
59. Eichler FS, Barker PB, Cox C, Edwin D, Ulug AM, Moser HW, et al. Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology 2002;58:901-7.
60. Salvan AM, Confort-Gouny S, Chabrol B, Cozzone PJ, Vion-Dury J. Brain metabolic impairment in non-cerebral and cerebral forms of X-linked adrenoleukodystrophy by proton MRS: identification of metabolic patterns by discriminant analysis. Magn Reson Med 1999;41:1119-26.
61. Wilken B, Dechent P, Brockmann K, Finsterbusch J, Baumann M, Ebell W, et al. Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation. Neuropediatrics 2003;34:237-46.
62. Wittsack HJ, Kugel H, Roth B, Heindel W. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease. J Magn Reson Imaging 1996;6:889-93.
63. Bianchi MC, Tosetti M, Fornai F, Alessandri MG, Cipriani P, De Vito G, et al. Reversible brain creatine deficiency in two sisters with normal blood creatine level. Ann Neurol 2000;47:511-3.
64. Cecil KM, Salomons GS, Ball WS, Jr., Wong B, Chuck G, Verhoeven NM, et al. Irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? Ann Neurol 2001;49:401-4.
65. Schulze A, Hess T, Wevers R, Mayatepek E, Bachert P, Marescau B, et al. Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: diagnostic tools for a new inborn error of metabolism. J Pediatr 1997;131:626-31.
66. Chabrol B, Salvan AM, Confort-Gouny S, Vion-Dury J, Cozzone PJ. Localized proton magnetic resonance spectroscopy of the brain differentiates the inborn metabolic encephalopathies in children. C R Acad Sci III 1995;318:985-92.
67. Confort-Gouny S, Chabrol B, Vion-Dury J, Mancini J, Cozzone PJ. MRI and localized proton MRS in early infantile form of neuronal ceroid-lipofuscinosis. Pediatr Neurol 1993;9:57-60.
68. Vion-Dury J, Salvan AM, Confort-Gouny S, Cozzone PJ. Atlas of brain proton magnetic resonance spectra. Part II: Inherited metabolic encephalopathies. J Neuroradiol 1998;25:281-9.